A similar result was reported previously (Nobusawa et al., 2009), showing that the mean time from first clinical symptom to the diagnosis of GBM is significantly longer in patients with IDH1 mutation (15.2 months vs. 3.9 months). The gene discussed is IDH1; the disease is glioblastoma.